Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Treasury Shares (2022 - 2025)

Historic Treasury Shares for SAB Biotherapeutics (SABSW) over the last 4 years, with Q3 2025 value amounting to $5.5 million.

  • SAB Biotherapeutics' Treasury Shares changed 0.0% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $5.5 million for FY2024, which is 0.0% changed from last year.
  • SAB Biotherapeutics' Treasury Shares amounted to $54665.0 in Q3 2025, which was up 20000.0% from -$54665.0 recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Treasury Shares peaked at $546658.0 during Q1 2022, and registered a low of -$54665.0 during Q4 2023.
  • For the 4-year period, SAB Biotherapeutics' Treasury Shares averaged around $207730.2, with its median value being $54665.0 (2022).
  • Within the past 5 years, the most significant YoY rise in SAB Biotherapeutics' Treasury Shares was 0.0% (2023), while the steepest drop was 0.0% (2023).
  • Over the past 4 years, SAB Biotherapeutics' Treasury Shares (Quarter) stood at $5.5 million in 2022, then changed by 0.0% to $5.5 million in 2023, then changed by 0.0% to $5.5 million in 2024, then changed by 0.0% to $5.5 million in 2025.
  • Its Treasury Shares stands at $5.5 million for Q3 2025, versus $5.5 million for Q2 2025 and $5.5 million for Q1 2025.